Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19-CD8-tLNP
- Development stage
- Unknown
- Lead developer
- Capstan Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CD19-CD8-tLNP is an innovative *in vivo* CAR T-cell therapy candidate developed by WestGene Biopharma. It utilizes a CD8-targeted lipid nanoparticle (tLNP) platform to deliver mRNA encoding a CD19-directed chimeric antigen receptor (CAR) directly to CD8+ T cells within the patient's body. The LNPs are functionalized with an anti-CD8 VHH (nanobody) to ensure selective uptake by T cells. Once delivered, the mRNA is translated, leading to the transient expression of CD19 CARs on the T-cell surface, which then target and deplete CD19-positive B cells. This "off-the-shelf" approach aims to eliminate the need for complex *ex vivo* cell manufacturing, lymphodepletion, and long wait times associated with traditional CAR T therapies. In early clinical trials for relapsed/refractory B-cell lymphoma, the drug has shown rapid B-cell clearance and a favorable safety profile.
- Other names
- CD8-tLNPCD-8-tLNPCD 8-tLNPCD8-targeted lipid nanoparticle platformCD-8-targeted lipid nanoparticle platformCD 8-targeted lipid nanoparticle platform
02
Targets
CD19 (B lymphocyte antigen CD19)CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on CD19-CD8-tLNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19-CD8-tLNP.